Maha Katabi is Director at Vera Therapeutics, Inc. (VERA). They have made 6 open-market trades across 3 companies since 2021, most recently 2024-03-25.
CIK 0001720685
5 open-market purchases totalling $26.2M since 2021, against 1 sale. Across 5 scored buys the stock is up 11.8% at ninety days, and 10.0 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 80% | 60% | 60% |
| Avg Move | +8.9% | +5.8% | +11.8% |
| Alpha | +8.9% | +4.7% | +10.0% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VERA | SELL | 2024-03-21 | 2024-03-25 | $40.85 | $52.1M | -7.2% | -1.2% | -13.7% |
| VERA | BUY | 2024-01-30 | 2024-02-01 | $31.00 | $5.0M | +11.1% | +19.8% | +8.9% |
| RYZB | BUY | 2023-09-19 | 2023-09-21 | $18.00 | $4.2M | +0.8% | -5.5% | +36.0% |
| VERA | BUY | 2022-02-10 | 2022-02-14 | $15.00 | $4.0M | +17.2% | +23.0% | -19.2% |
| AVTE | BUY | 2021-07-02 | 2021-07-06 | $14.00 | $5.0M | -22.0% | -31.0% | -1.8% |
| VERA | BUY | 2021-05-18 | 2021-05-18 | $11.00 | $8.0M | +37.2% | +22.7% | +35.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.